Citigroup Inc Anavex Life Sciences Corp. Transaction History
Citigroup Inc
- $169 Billion
- Q3 2024
A detailed history of Citigroup Inc transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Citigroup Inc holds 60,800 shares of AVXL stock, worth $736,288. This represents 0.0% of its overall portfolio holdings.
Number of Shares
60,800
Previous 53,509
13.63%
Holding current value
$736,288
Previous $225,000
53.33%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding AVXL
# of Institutions
155Shares Held
27.3MCall Options Held
515KPut Options Held
838K-
Black Rock Inc. New York, NY6.39MShares$77.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.74MShares$57.4 Million0.0% of portfolio
-
State Street Corp Boston, MA3.07MShares$37.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$22.8 Million0.0% of portfolio
-
Nwam LLC Mercer Island, WA910KShares$11 Million0.32% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $944M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...